Targeted and Synergistic Codelivery of Chemotherapeutic and Nucleic Acid Drugs by Liposome-Coated MPDA Nanoparticles for Advanced Prostate Cancer Treatment
IF 8.3 2区 材料科学Q1 MATERIALS SCIENCE, MULTIDISCIPLINARY
{"title":"Targeted and Synergistic Codelivery of Chemotherapeutic and Nucleic Acid Drugs by Liposome-Coated MPDA Nanoparticles for Advanced Prostate Cancer Treatment","authors":"Liang Dai, Wangteng Ma, Zixuan Song, Binwei Lu, Yuchu He, Jidong Zhang, Dapeng Wei, Baibing Wang, Guangming Li, Dawei Gao, Yimin Wang","doi":"10.1021/acsami.4c17384","DOIUrl":null,"url":null,"abstract":"Docetaxel (DTX)-based chemotherapy is the primary therapeutic approach for advanced prostate cancer (PCa) when endocrine therapy proves ineffective. Traditional chemotherapy exhibits poor specificity and induces severe side effects, such as immunosuppression, neurotoxicity, and hypersensitivity. In this study, we aimed to develop a new targeted nanodrug delivery system to accurately identify PCa cells and deliver drugs. We prepared mesoporous polydopamine (MPDA) nanoparticles using a one-pot method. After loading DTX onto MPDA, siRNA was attached to the surface, which was coated with polyethylene glycol lipids film (PEG-Lips); together, this formed MDS@L. The aptamer A10-3.2 was coupled to the surface of PEG-Lips to obtain MDS@LA, which was characterized using different techniques, including transmission electron microscopy and Fourier transform infrared spectroscopy. MDS@LA exhibited excellent stability, acid-responsive release, and photothermal properties, enhancing its antitumor effects. Both in vitro and in vivo experiments revealed that MDS@LA precisely targeted PCa cells and effectively delivered DTX and siRNA, leading to significant inhibition of PCa cell growth and proliferation. This versatile nanoplatform offers a promising, precise, and efficient therapeutic approach for advanced PCa, addressing the limitations of conventional chemotherapy.","PeriodicalId":5,"journal":{"name":"ACS Applied Materials & Interfaces","volume":"23 1","pages":""},"PeriodicalIF":8.3000,"publicationDate":"2025-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Materials & Interfaces","FirstCategoryId":"88","ListUrlMain":"https://doi.org/10.1021/acsami.4c17384","RegionNum":2,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MATERIALS SCIENCE, MULTIDISCIPLINARY","Score":null,"Total":0}
引用次数: 0
Abstract
Docetaxel (DTX)-based chemotherapy is the primary therapeutic approach for advanced prostate cancer (PCa) when endocrine therapy proves ineffective. Traditional chemotherapy exhibits poor specificity and induces severe side effects, such as immunosuppression, neurotoxicity, and hypersensitivity. In this study, we aimed to develop a new targeted nanodrug delivery system to accurately identify PCa cells and deliver drugs. We prepared mesoporous polydopamine (MPDA) nanoparticles using a one-pot method. After loading DTX onto MPDA, siRNA was attached to the surface, which was coated with polyethylene glycol lipids film (PEG-Lips); together, this formed MDS@L. The aptamer A10-3.2 was coupled to the surface of PEG-Lips to obtain MDS@LA, which was characterized using different techniques, including transmission electron microscopy and Fourier transform infrared spectroscopy. MDS@LA exhibited excellent stability, acid-responsive release, and photothermal properties, enhancing its antitumor effects. Both in vitro and in vivo experiments revealed that MDS@LA precisely targeted PCa cells and effectively delivered DTX and siRNA, leading to significant inhibition of PCa cell growth and proliferation. This versatile nanoplatform offers a promising, precise, and efficient therapeutic approach for advanced PCa, addressing the limitations of conventional chemotherapy.
期刊介绍:
ACS Applied Materials & Interfaces is a leading interdisciplinary journal that brings together chemists, engineers, physicists, and biologists to explore the development and utilization of newly-discovered materials and interfacial processes for specific applications. Our journal has experienced remarkable growth since its establishment in 2009, both in terms of the number of articles published and the impact of the research showcased. We are proud to foster a truly global community, with the majority of published articles originating from outside the United States, reflecting the rapid growth of applied research worldwide.